Latest Diagnostics News

Waratah Minerals has significantly expanded the Spur Gold Corridor with high-grade gold mineralisation, revealing new zones of visible gold and advancing copper-gold exploration at its flagship Spur Project in New South Wales.

Pacific Edge has successfully closed its Share Purchase Plan, raising $4.7 million and bringing total new equity to $20.7 million, surpassing initial targets. The capital raise awaits shareholder approval at the upcoming Annual Meeting.

Babylon Pump & Power has completed two key acquisitions, expanding its water services platform and enhancing earnings with minimal integration risk. These moves position the company for sustained growth in the mining services sector.

Resmed Inc. reported a robust 10% revenue increase and a 19% rise in operating profit for fiscal 2025, alongside a 13% dividend hike, driven by strong demand for sleep and breathing health devices and growth in digital health software.

Pro Medicus Limited has entered a strategic financing arrangement with 4DMedical to accelerate the development and commercialization of cutting-edge lung function imaging software.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

4DMedical reports a 56% revenue surge in FY25 alongside a strategic $10 million investment from Pro Medicus, advancing its CT, VQ™ lung imaging technology towards FDA clearance.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Omega Oil and Gas reports strong appraisal progress at its Canyon Project, highlighting premium light crude oil and multiple stacked pay zones, supported by a robust $15.1 million pro forma cash position.